why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat
300×250 Ad Slot

Drug FDA Status

Showing 139 of 139 result(s) (Page 14 of 14)
Drug Name: Zavzpret

Active Ingredient: zavegepant

Approval Date: 2023-03-09

Description: To treat migraine

Drug Name: Skyclarys

Active Ingredient: omaveloxolone

Approval Date: 2023-02-28

Description: To treat Friedrich's ataxia
Drug Trials Snapshots

Drug Name: Filspari

Active Ingredient: sparsentan

Approval Date: 2023-02-17

Description: To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression

Drug Name: Lamzede

Active Ingredient: velmanase alfa-tycv

Approval Date: 2023-02-16

Description: To treat non-central nervous system manifestations of alpha-mannosidosis

Drug Name: Jesduvroq

Active Ingredient: daprodustat

Approval Date: 2023-02-01

Description: To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months
Press Release
Drug Trials Snapshot

Drug Name: Orserdu

Active Ingredient: elacestrant

Approval Date: 2023-01-27

Description: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Drug Trials Snapshot

Drug Name: Jaypirca

Active Ingredient: pirtobrutinib

Approval Date: 2023-01-27

Description: To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor
Drug Trials Snapshot

Drug Name: Brenzavvy

Active Ingredient: bexagliflozin

Approval Date: 2023-01-20

Description: To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
Drug Trials Snapshot

Drug Name: Leqembi

Active Ingredient: lecanemab-irmb

Approval Date: 2023-01-06

Description: To treat Alzheimer's disease
Press Release

300×250 Ad Slot